AstraZeneca is disappointed to announce a shortfall in planned COVID-19 vaccine shipments to the European Union (EU) despite working tirelessly to accelerate supply.
The Company had previously communicated that it is facing shortfalls from its European supply chain due to lower-than-expected output from the production process. It had also stated that it was looking to compensate for part of this shortfall by sourcing vaccines from its international supply network.
Half of the EU’s supply in the second quarter, and 10m doses in the first quarter were due to be sourced from the Company’s international supply chain. Unfortunately, export restrictions will reduce deliveries in the first quarter, and are likely to affect deliveries in the second quarter.
The Company started delivery of the vaccine to the EU in February. Despite the challenges, it aims to deliver 100m doses in the first half of 2021, of which 30m are due to be delivered in the first quarter.
The Company is collaborating with the EU Commission and Member States to address the supply challenges. It remains confident that productivity in its EU supply chain will continue to improve, to help protect millions of Europeans against the virus.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.